Article info
PDFResearch Article
Real-world efficacy and safety of nivolumab in previously-treated metastatic renal cell carcinoma, and association between immune-related adverse events and survival: the Italian expanded access program
- ↵a +39 02 2390 4449 elena.verzoni{at}istitutotumori.mi.it
- ↵b cartenigiacomo{at}gmail.com
- ↵c enrico.cortesi{at}uniroma1.it
- ↵d diana.giannarelli{at}gmail.com
- ↵e degio1989{at}gmail.com
- ↵f sabbrob{at}unimore.it
- ↵g sebabuti{at}libero.it
- ↵h sabrinarossetti{at}virgilio.it
- ↵i francesco.cognetti{at}ifo.gov.it
- ↵j fraraste{at}gmail.com
- ↵k alberto.sobrero{at}hsanmartino.it
- ↵l d.turci{at}ausl.ra.it
- ↵m csternberg{at}scamilloforlanini.rm.it
- ↵n camillo.porta{at}gmail.com
- ↵o f.cappuzzo{at}gmail.com
- ↵p giampaolo.tortora{at}univr.it
- ↵q davide.tassinari{at}auslromagna.it
- ↵r s.panni{at}asst-cremona.it
- ↵s antonio.pazzola{at}aousassari.it
- ↵t oncologia.polecce{at}ausl.le.it
- ↵u alessandra.raimondi{at}istitutotumori.mi.it
- ↵v ugo.degiorgi{at}irst.emr.it
- ↵w giuseppe.procopio{at}istitutotumori.mi.it
Citation
Real-world efficacy and safety of nivolumab in previously-treated metastatic renal cell carcinoma, and association between immune-related adverse events and survival: the Italian expanded access program
Publication history
- Received November 14, 2018
- Accepted March 26, 2019
- First published April 3, 2019.
Online issue publication
April 03, 2019
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© The Author(s).
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.